In a report released today, Peter Welford from Jefferies maintained a Hold rating on AstraZeneca (AZN – Research Report), with a price target of £114.00. The company’s shares opened today at ...

UK pharmaceutical giant AstraZeneca has entered into an exclusive license agreement with China's CSPC Pharmaceutical Group (CSPC) to advance the development of an early stage, novel small molecule ...

AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) ...

AstraZeneca said on Monday (Oct 7) it would pay up to US$1.92 billion to CSPC Pharmaceutical Group in an exclusive licence agreement to boost the Anglo-Swedish drugmaker’s cardiovascular pipeline.

Oct 7 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday it would pay up to $1.92 billion to CSPC Pharmaceutical Group Ltd (1093.HK), opens new tab in an exclusive licence agreement to ...

AstraZeneca (NASDAQ:AZN) is looking to boost its cardiovascular pipeline through an exclusive license agreement with CSPC Pharmaceutical Group (CSPC). As part of the deal, AstraZeneca will pay $ ...

AstraZeneca will pay CSPC $100 million upfront, with potential for up to $1.92 billion in milestone payments. Airsupra Phase 3b trial shows significant reduction in severe asthma exacerbations ...

AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug. The deal, which covers a potential rival to an Eli Lilly prospect, positions AstraZeneca ...

AstraZeneca, the UK’s largest drugmaker valued at $140bn, has reportedly contacted Gilead Sciences, an American biopharmaceutical company with a market value of approximately $96bn, regarding a ...

(Reuters) -AstraZeneca said on Monday it would pay up to $1.92 billion to CSPC Pharmaceutical Group Ltd in an exclusive licence agreement to boost the Anglo-Swedish drugmaker's cardiovascular ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca ...

Barclays analyst Emily Field maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The company’s shares closed last Friday at p11,686.00.